NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free HUMA Stock Alerts $6.45 +0.03 (+0.47%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$6.18▼$6.9650-Day Range$2.87▼$6.4252-Week Range$1.96▼$6.96Volume4.16 million shsAverage Volume1.22 million shsMarket Capitalization$768.07 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Humacyte alerts: Email Address Humacyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside22.3% Upside$8.00 Price TargetShort InterestHealthy4.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 23 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.90) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.62 out of 5 starsMedical Sector704th out of 928 stocksBiological Products, Except Diagnostic Industry121st out of 153 stocks 2.4 Analyst's Opinion Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHumacyte has only been the subject of 3 research reports in the past 90 days.Read more about Humacyte's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.99% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Humacyte has recently increased by 13.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUMA. Previous Next 2.8 News and Social Media Coverage News SentimentHumacyte has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Humacyte this week, compared to 2 articles on an average week.Search Interest24 people have searched for HUMA on MarketBeat in the last 30 days. This is an increase of 118% compared to the previous 30 days.MarketBeat Follows14 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have not sold or bought any company stock.Percentage Held by Insiders23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Humacyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($0.90) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 50.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Humacyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsTiny AI projects with huge promise hiding in plain sight …I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.Click here to find out who they are. About Humacyte Stock (NASDAQ:HUMA)Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More HUMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUMA Stock News HeadlinesMay 15 at 2:22 AM | americanbankingnews.comHumacyte (NASDAQ:HUMA) Receives Buy Rating from BenchmarkMay 14 at 10:45 AM | msn.comHumacyte extends gains as FDA reviews blood vessel productMay 13 at 7:39 PM | markets.businessinsider.comBenchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)May 13 at 7:39 PM | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q1 2024 Earnings Call TranscriptMay 13 at 8:11 AM | finance.yahoo.comHumacyte Inc (HUMA) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 13 at 8:11 AM | finance.yahoo.comHumacyte to Participate at Upcoming Investor Conferences in MayMay 13 at 8:00 AM | globenewswire.comHumacyte to Participate at Upcoming Investor Conferences in MayMay 12 at 4:03 AM | americanbankingnews.comHumacyte (NASDAQ:HUMA) Trading 6.2% Higher May 11, 2024 | finance.yahoo.comQ1 2024 Humacyte Inc Earnings CallMay 10, 2024 | benzinga.comPeering Into Humacyte's Recent Short InterestMay 10, 2024 | finance.yahoo.comHumacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic AdvancesMay 10, 2024 | msn.comHumacyte GAAP EPS of -$0.29 misses by $0.06May 10, 2024 | globenewswire.comHumacyte First Quarter 2024 Financial Results and Business UpdateMay 9, 2024 | msn.comHumacyte Q1 2024 Earnings PreviewMay 9, 2024 | americanbankingnews.comHumacyte (HUMA) Scheduled to Post Earnings on FridayMay 6, 2024 | globenewswire.comHumacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024May 6, 2024 | americanbankingnews.comHead to Head Survey: Humacyte (NASDAQ:HUMA) vs. Cidara Therapeutics (NASDAQ:CDTX)April 20, 2024 | msn.comA U.S. Senator Just Bought this Tiny Stock – It’s Up 15% TodayApril 18, 2024 | msn.comA U.S. Senator Just Bought this Tiny Stock - It's Up 15% TodayApril 18, 2024 | benzinga.comAlly Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On ThursdayApril 18, 2024 | msn.comTuberville’s Trading Raises Questions: Senator Sells Put Options, Invests in Small Biotech Tied to Ukraine-Russia ConflictApril 17, 2024 | ca.investing.comU.S. Senator Tommy Tuberville Just Reported a Purchase of $HUMA stockApril 15, 2024 | finance.yahoo.comHumacyte, Inc. (HUMA) Interactive Stock Chart - Yahoo FinanceApril 8, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Humacyte (HUMA)March 26, 2024 | globenewswire.comHumacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024See More Headlines Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today5/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees183Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+19.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-284.01% Return on Assets-71.15% Debt Debt-to-Equity Ratio1.20 Current Ratio4.52 Quick Ratio4.52 Sales & Book Value Annual Sales$1.57 million Price / Sales506.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book51.38Miscellaneous Outstanding Shares119,080,000Free Float91,576,000Market Cap$795.45 million OptionableOptionable Beta1.27 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Laura E. Niklason M.D. (Age 61)Ph.D., Founder, President, CEO & Director Comp: $717.85kMr. Dale A. Sander (Age 64)CFO, Chief Corporate Development Officer & Treasurer Comp: $667.45kDr. Shamik J. Parikh M.D. (Age 51)Chief Medical Officer Comp: $514.72kDr. Juliana L. Blum Ph.D.Co-Founder & Executive AdvisorDr. Heather Ledbetter Prichard Ph.D. (Age 46)Chief Operating Officer Comp: $576.44kMs. Sabrina OsborneExecutive Vice President of Business Strategy & PeopleMr. William John Scheessele (Age 52)Chief Commercial Officer Mr. Harold AltersonSenior Vice President of QualityDr. Yang Cao M.D. (Age 58)Ph.D., Chief Regulatory Officer More ExecutivesKey CompetitorsCARGO TherapeuticsNASDAQ:CRGXREGENXBIONASDAQ:RGNXPrime MedicineNYSE:PRMEMesoblastNASDAQ:MESORelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsiders & InstitutionsAnson Funds Management LPBought 50,000 shares on 5/14/2024Ownership: 0.042%Vanguard Group Inc.Bought 896,415 shares on 5/10/2024Ownership: 3.376%GSA Capital Partners LLPSold 238,032 shares on 5/3/2024Ownership: 0.167%Capstone Investment Advisors LLCBought 312,400 shares on 5/1/2024Ownership: 0.262%Hartline Investment CorpBought 22,450 shares on 4/30/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions HUMA Stock Analysis - Frequently Asked Questions Should I buy or sell Humacyte stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HUMA shares. View HUMA analyst ratings or view top-rated stocks. What is Humacyte's stock price target for 2024? 4 brokers have issued 12-month price objectives for Humacyte's stock. Their HUMA share price targets range from $4.00 to $15.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 22.3% from the stock's current price. View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts. How have HUMA shares performed in 2024? Humacyte's stock was trading at $2.84 at the start of the year. Since then, HUMA shares have increased by 130.3% and is now trading at $6.54. View the best growth stocks for 2024 here. When is Humacyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our HUMA earnings forecast. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) released its quarterly earnings results on Friday, March, 22nd. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same period in the prior year, the business posted ($0.21) EPS. What ETFs hold Humacyte's stock? ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS). Who are Humacyte's major shareholders? Humacyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.38%), Private Advisor Group LLC (0.27%), Capstone Investment Advisors LLC (0.26%), GSA Capital Partners LLP (0.17%), Seven Grand Managers LLC (0.04%) and Anson Funds Management LP (0.04%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason, Michael T Constantino and William John Scheessele. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HUMA) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDoes this make you sick?Allegiance GoldThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
